BioTuesdays

MedMira receives Breakthrough Device Designation for syphilis antibody test

MedMira (TSXV: MIR) has announced that the FDA has granted Breakthrough Device Designation to its Multiplo Complete Syphilis (TP/nTP) Antibody Test.

According to MedMira, unlike conventional laboratory-based testing approaches that may require separate testing procedures, Multiplo Complete Syphilis (TP/nTP) Antibody Test simultaneously detects treponemal and non-treponemal antibodies from a single fingerstick whole blood specimen, delivering both results in a rapid, visually interpreted format without specialized instrumentation. The test uses MedMira’s proprietary Rapid Vertical Flow Technology.

In a statement, Hermes Chan, CEO of MedMira, commented, “This is an extraordinary milestone for MedMira and a tremendous recognition of the dedication, perseverance, and scientific innovation of our entire team. The FDA’s decision reinforces the potential significance of our technology and represents an important step as we advance our development program toward the U.S. market.”

POWERED BY

Stay Ahead in Healthcare & Life Sciences